Quarterly report pursuant to Section 13 or 15(d)

Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail)

v3.22.1
Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Outstanding and nonvested, Beginning Balance, Number of Shares [1] 3,400    
Granted, Number of Shares [2] 1,971    
Vested, Number of Shares (750)    
Forfeited, Number of Shares [3] (126)    
Outstanding and nonvested, Ending Balance, Number of Shares [1] 4,495   3,400
Number of Shares, Expected to vest [4] 3,787    
Outstanding and nonvested, Beginning Balance, Weighted Average Grant Date Fair Value Per Share [1] $ 45.26    
Granted, Weighted Average Grant Date Fair Value Per Share [2] 36.63    
Vested, Weighted Average Grant Date Fair Value Per Share 48.77    
Forfeited, Weighted Average Grant Date Fair Value Per Share [3] 45.41    
Outstanding and nonvested, Ending Balance, Weighted Average Grant Date Fair Value Per Share [1] 40.89   $ 45.26
Expected to vest, Ending Balance, Weighted Average Grant Date Fair Value Per Share [4] $ 40.69    
SARs [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Awards Outstanding, Beginning Balance [5] 2,622    
Granted, Number of Awards 0 0  
Exercised, Number of Awards (17)    
Forfeited, Number of Awards 0    
Number of Awards Outstanding, Ending Balance [5] 2,605   2,622
Number of Awards Exercisable, Ending Balance [6] 2,605    
Number of Awards Vested and expected to vest, Ending Balance 2,605    
Weighted Average Exercise Price Per Award Outstanding, Beginning Balance [5] $ 27.10    
Granted, Weighted Average Exercise Price Per Award 0    
Exercised, Weighted Average Exercise Price Per Award [6] 22.57    
Forfeited, Weighted Average Exercise Price Per Award 0    
Weighted Average Exercise Price Per Award Outstanding, Ending Balance [5] 27.13   $ 27.10
Exercisable, Weighted Average Exercise Price Per Award, Ending Balance [6] 27.13    
Weighted Average Exercise Price Per Award, Vested and expected to vest, Ending Balance $ 27.13    
Weighted Average Remaining Contractual Term Outstanding [5] 3 years 7 months 6 days   3 years 9 months 18 days
Exercisable Weighted Average Remaining Contractual Term [6] 3 years 7 months 6 days    
Weighted Average Remaining Contractual Term, Vested and expected to vest 3 years 7 months 6 days    
Aggregate Intrinsic Value Outstanding [5],[7] $ 10.7   $ 36.3
Exercisable, Aggregate Intrinsic Value [6],[7] 10.7    
Aggregate Intrinsic Value, Vested and expected to vest [7] $ 10.7    
[1] Includes 1,357,760 and 913,388 performance-based restricted stock units as of March 31, 2022 and December 31, 2021, respectively, which represents the maximum amount that can vest.
[2] Includes 538,482 performance-based restricted stock units.
[3] Includes 94,110 performance-based restricted stock units
[4] Includes 734,564 performance-based restricted stock units.
[5] Includes 0.8 million performance condition SARs as of both March 31, 2022 and December 31, 2021, which represents the maximum amount that can vest
[6] Includes 0.8 million performance condition SARs.
[7] The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the SARs.